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Summary
The essential role of the sphingosine 1-phosphate
(S1P) receptor S1P1 in regulating lymphocyte traffick-
ing was demonstrated with the S1P1-selective nano-
molar agonist, SEW2871. Despite its lack of charged
headgroup, the tetraaromatic compound SEW2871
binds and activates S1P1 through a combination of
hydrophobic and ion-dipole interactions. Both S1P
and SEW2871 activated ERK, Akt, and Rac signaling
pathways and induced S1P1 internalization and re-
cycling, unlike FTY720-phosphate, which induces re-
ceptor degradation. Agonism with receptor recycling
is sufficient for alteration of lymphocyte trafficking by
S1P and SEW2871. S1P1 modeling and mutagenesis
studies revealed that residues binding the S1P head-
group are required for kinase activation by both S1P
and SEW2871. Therefore, SEW2871 recapitulates the
action of S1P in all the signaling pathways examined
and overlaps in interactions with key headgroup bind-
ing receptor residues, presumably replacing salt-
bridge interactions with ion-dipole interactions.
Introduction
Sphingosine 1-phosphate (S1P), through its high affin-
ity G protein-coupled receptors S1P1–5, is a physiologi-
cal mediator with widespread effects upon multiple
physiological systems [1–9]. It regulates heart rate [10],
coronary artery blood flow [11], blood pressure [12], en-
dothelial integrity in lung [13, 14], and, most recently,
has been shown to regulate the recirculation of lympho-
cytes [15–19]. Many of the physiologically relevant
functions occur in the low nanomolar range, including
activation of endothelial nitric-oxide synthase [20, 21],
vasorelaxation [22], and inhibition of thymic egress and*Correspondence: hrosen@scripps.edulymphocyte recirculation [15]. Free plasma levels of
S1P are tightly regulated by protein binding to albumin
and high-density lipoprotein and by abundant extracel-
lular lipid phosphatases to avoid the deleterious effects
of systemic S1P receptor subtype activation at high
concentrations of ligand, such as bradycardia and cor-
onary artery vasospasm [11, 23]. The choice of S1P,
through its receptor S1P1, as an acute regulator of the
number of blood lymphocytes may represent an in-
teresting evolutionary choice by the immune system,
which evolved after the circulatory system. This has
been supported by receptor-selective agonists [24] and
selective receptor deletional studies [25, 26]. The dis-
covery of potent synthetic agonists of the S1P recep-
tors such as FTY720-phosphate (now in clinical trials
for prevention of renal allograft rejection) has rapidly
extended the field into therapeutics, whereas many of
the key features of system regulation at a molecular
level remain inadequately understood.
We have recently shown that SEW2871, originally
identified by high-throughput screening of commercial
chemical libraries with a 384-well-format FLIPR calcium-
flux assay, can cause lymphopenia via an S1P1-depen-
dent mechanism [24]. It was also idenfified by high-
throughput screening with GTPγS binding assay [27]. In
the present study, we examined the signaling pathways
and receptor fate in cells activated by SEW2871 and its
structurally related analogs. Upon agonist stimulation,
S1P1 has been reported to internalize and colocalize
with endocytic vesicles and lysosomes [28, 29]. The
high-affinity ligand S1P induces the recycling of S1P1
back to the plasma membrane via the endosomal path-
way [28]. However, FTY720-phosphate was recently re-
ported to induce internalization and degradation of
S1P1, resulting in receptor downregulation and lympho-
cyte sequestration in vivo [25, 30]. Therefore, it was of
interest to examine whether the mode of action of
SEW2871 produces functional antagonism or long-term
activation of postreceptor signaling mechanisms. This
study could allow us to narrow down the signals that
need to be considered in unraveling the control of lym-
phocyte recirculation.
Furthermore, the two-site binding model for S1P [31]
raised questions about the extent to which receptor-
ligand interactions for the tetraaromatic structures
overlapped those for S1P, particularly with regard to re-
capitulating any headgroup interactions that might be
essential for proper conformational changes in the re-
ceptor in response to agonist binding. We therefore
used a combination of computational modeling, recep-
tor mutagenesis, and chemical ligands to examine the
role of headgroup interactions in S1P1 signaling by ago-
nists of different structures.
Understanding the signaling properties of the S1P re-
ceptors within the context of both model cell systems
in vitro and within tissues in vivo will have an important
prospective impact on S1P pathway therapeutics, rele-
vant to immune, cardiovascular, and respiratory dis-
eases as well as cancer [1, 32, 33].
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b
sBoth S1P and SEW2871 Induce Activation of MAP
Kinase and Akt Pathways a
sS1P has been reported to activate mitogen-activated
protein kinases (MAP kinases) in many systems [34–
(40]. Therefore, we examined the phosphorylation of ex-
tracellular signal-regulated kinase 1 (ERK1) and ERK2 i
min CHO cells stably transfected with S1P1. Phosphory-
lation of both ERK1 and ERK2 was increased in a con- S
icentration-dependent manner after stimulation of cells
with S1P for 5 min (Figure 1A). SEW2871, a S1P1 re- n
oceptor-selective agonist, also induced concentration-
dependent phosphorylation of ERK1 and ERK2. Both f
wS1P and SEW2871 induced phosphorylation of Akt
(Figures 1A, 1B, and 1C), confirming that Akt is involved S
pin the downstream signaling events initiated by S1P1
[21, 41–43]. t
tSEW2871 is an S1P1-selective full agonist (inducing
responses equivalent to 100% of those seen with the b
Aphysiological ligand S1P) in GTPγS binding, calcium
flux, and cell migration assays [24]. S1P1 selectivity of s
lSEW2871 action on kinase activation is shown in Figure
1A. ERK1/2 and Akt phosphorylation was observed in tFigure 1. Both S1P and SEW2871 Induce
Phosphorylation of ERK1/2 and Akt in CHO
Cells Stably Transfected with S1P1
(A) CHO cells stably transfected with either
S1P1 or S1P3 were serum starved and stim-
ulated with either S1P or SEW2871 at the in-
dicated concentrations for 5 min. Western
blot analyses of phospho-ERK1/2, total
ERK1/2, phospho-Akt, and total Akt levels
were shown. Data are representative autora-
diograms of several experiments. Vector-
transfected CHO cells contained only the
minimal levels of pERK1/2 and pAkt (data
not shown).
(B) Structure of sphingosine 1-phosphate
(S1P).
(C) SEW2871 and its analogs.
(D) AFD(R).esponse to SEW2871 stimulation in S1P1-CHO cells
ut not S1P3-CHO cells (Figure 1A). However, S1P, a non-
elective agonist, induced phosphorylation of ERK1/2
nd Akt in both S1P1-CHO and S1P3-CHO cells (data
hown for S1P1-CHO cells only).
The relative potencies of S1P, AFD(R), and SEW2871
Figures 1B–1D) for kinase activation and GTPγS bind-
ng were determined by EC50 measurement. S1P was
ore potent in inducing ERK/Akt phosphorylation than
EW2871. For instance, S1P at 5 nM was sufficient to
nduce maximal phosphorylation of Akt, whereas 500
M of SEW2871 was needed to induce the same level
f Akt phosphorylation (Figure 1A). This relative dif-
erence in potency on downstream signal generation
as even more obvious when comparing AFD(R) to
EW2871. As shown in Figures 2A–2C, AFD(R) induced
hosphorylation of ERK and Akt at ligand concentra-
ions that were three to four orders of magnitude lower
han SEW2871 (Table 1). This suggested that ligand
inding and downstream signaling were greatest for
FD(R), intermediate for S1P, and least for SEW2871 at
ubnanomolar ligand concentrations. However, all three
igands were full agonists inducing phosphorylation of
hese signaling molecules to the same extent, provided
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705Figure 2. Agonist Dose Response Curves of Phosphorylation of ERK1/2 and Akt upon Stimulation with S1P1 Agonists
(A–C) CHO cells stably transfected with S1P1 were serum starved and stimulated with AFD(R), S1P, or SEW2871 at the indicated concentra-
tions for 5 min. The band intensities of phosphoproteins were integrated, normalized against total ERK or Akt, and expressed as percentage
of maximal phosphorylation upon AFD(R) (%), S1P (,), and SEW2871 (C) stimulation. Data represent mean ± SD of three independent experi-
ments.
(D–F) Time course of phosphorylation of ERK1/2 and Akt upon stimulation with SEW2871. CHO cells stably transfected with S1P1 were serum
starved and stimulated with SEW2871 at the indicated concentrations (1 nM to 5 M) for 5 min, 1 hr, and 4.5 hr. Band intensities corresponding
to (D) pERK1, (E) pERK2, and (F) pAkt were quantitated by image analysis and normalized against total ERK or Akt. Data are expressed as
percentage of the level of phosphorylation obtained at 5 M SEW2871 for 5 min stimulation. Nontransfected CHO cells were included as
negative control.
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706Table 1. EC50 Values (nM) of S1P1 Agonists from GTPγ35S Assay and Downstream Phosphorylation of Akt, ERK1, and ERK2
GTPγ35S pAkt pERK1 pERK2
AFD(R) 0.032 ± 0.006 (n = 3) 0.007 ± 0.005 0.03 ± 0.01 0.01 ± 0.005
S1P 0.4 ± 0.24 (n = 6) 0.07 ± 0.04 0.09 ± 0.04 0.07 ± 0.04
SEW2871 13.8 ± 8.3 (n = 3) 104 ± 34 141 ± 62 46 ± 20
Data for GTPγ35S assay are average ± standard error from three to six experiments, and data for kinase assay are average ± standard error
from triplicate experiments.that high enough ligand concentrations were used. The 5
orelative affinities of S1P1 for these ligands were exam-
ined in a competition assay by measuring displacement a
iof [33P]-labeled S1P by cold S1P and AFD(R). The IC50
values were 2.2 ± 0.5 nM for S1P and 5.5 ± 2.0 nM for
AFD(R). The IC50 for SEW2871 was reported to be 37
nM [27].
We next examined the time course of phosphoryla-
tion of ERK1, ERK2, and Akt for AFD(R), S1P, and
SEW2871. The kinetics of phosphorylation was similar
for all three ligands, and data is shown for SEW2871
(Figures 2D–2F). As shown in Figures 2D–2E, both ERK1
and ERK2 phosphorylation was maximal at 5 min stim-
ulation, and the level of phospho-ERK decreased with
time, but the level of phospho-ERK remained elevated
for at least 4.5 hr of stimulation. On the other hand, Akt
phosphorylation was near maximal level up to 1 hr of
stimulation with SEW2871 but decreased to basal level
by 4.5 hr (Figure 2F).
To help define the G proteins that are involved in the
agonist-induced Akt and ERK phosphorylation, we ex-
amined the effect of Gi/o inhibitor pertussis toxin (PTx)
[44]. Preincubation of the S1P1-CHO cells with PTx
completely inhibited both ERK and Akt phosphorylation
in response to AFD(R) and SEW2871 (Figure 3A). The
PTx-induced inhibition of the phosphorylation was al-
most complete when stimulated with S1P (Figure 3A).
This suggests that all the agonists tested share the ERK
and Akt signaling pathways through activation of Gi/o
protein and that Gi/o protein activation is formally up-
stream of kinase recruitment.
Both S1P and SEW2871 Induce Activation
of Rac GTPase
Small GTPases of the Rho family, including Rac1, Rho,
and Cdc42, play an important role in cytoskeletal
changes and cell motility in response to receptor stimu-
lation [45, 46]. S1P has been reported to elicit either
stimulatory or inhibitory effects on cell migration, de-
pending on cell type and availability of S1P receptor
subtypes [47, 48]. We have examined whether S1P acti-
vates Rac1 in CHO cells stably transfected with S1P1. F
In order to pull down only the active (GTP bound) Rac D
with GSH-Sepharose beads, we utilized GST-tagged
(
p21 binding domain of p21-activated protein kinase 1 A
(PAK1) [47]. After S1P stimulation of S1P1-CHO cells c
mfor 2–5 min, Rac was activated significantly at 2 min,
acompared to the negative control (Figure 3B). SEW2871
(also activated Rac both at 2 min and 5 min, suggesting
wthat Rac activation is a common signaling pathway of
o
S1P1 agonist stimulation. Rac activation was increased w
in an agonist-concentration-dependent manner, and G
athe potency was higher for S1P than SEW2871. S1P ats consistent with that on ERK and Akt phosphorylation.
igure 3. S1P1-Mediated ERK1/2 and Akt Phosphorylation is Gi/o
ependent
A) ERK1/2 and Akt phosphorylation upon stimulation with S1P,
FD(R), and SEW2871 is Gi/o dependent. S1P1-CHO cells were in-
ubated with pertussis toxin at the final concentration of 100 ng/
l for 3 hr prior to agonist stimulation and analyzed for pERK1/2
nd pAkt levels.
B) Activated Rac pull-down assay. CHO cells stably transfected
ith S1P1 were serum starved and stimulated with S1P at 50 nM
r SEW2871 at 500 nM for 2 and 5 min. Active (GTP bound) Rac
as pulled down with GST-PBD (p21 binding domain of PAK1) and
SH-Sepharose beads. Western blot analysis of the eluents with
nti-Rac antibody is shown.0 nM caused maximal Rac activation, whereas 5 M
f SEW2871 was required to induce the maximal Rac
ctivation. This difference in potency on Rac activation
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707In addition, we have observed cytoskeletal changes,
such as ruffle formation and increased stress fiber for-
mation, upon SEW2871 stimulation of S1P1-CHO cells,
which is consistent with the Rac activation (see Figures
S1 and S2 available with this article online).
Both S1P and SEW2871 Induce S1P1 Receptor
Internalization and Recycling
S1P1 has been reported to internalize and colocalize
with endocytic vesicles, caveolae, and lysosomes upon
S1P stimulation and to recycle back to the plasma
membrane [20, 28, 29, 49]. We have examined whether
SEW2871 also induces S1P1 receptor internalization
and recycling in HEK293 cells that are stably trans-
fected with GFP-tagged S1P1. SEW2871 (500 nM) in-
duced S1P1 receptor internalization to the similar ex-
tent as S1P (100 nM) (Figure 4). Both SEW2871 (500
nM) and S1P (100 nM) induced the receptors to recycle
back to the plasma membrane when cells were washed
and treated with cycloheximide (Figure 4). The receptor
recycling was observed as early as 15 min, and it was
increased slowly up to 4 hr. On the other hand, FTY720-
phosphate induced S1P1 receptor internalization with-
out recycling (Figure 4).
Activation of S1P1 by SEW2871 Requires Polar
Receptor Residues that Support Salt-Bridge
Interactions with the S1P Headgroup
It has been reported that the basic side chains of
Arg120 (3.28) and Arg292 (7.34) of the S1P1 receptor
support electrostatic interactions with the phosphate
group of S1P, whereas the acidic side chain Glu121
(3.29) ion pairs with the ammonium moiety of S1P, lead-
ing to S1P headgroup interaction with its receptor [31].
SEW2871 does not contain a charged headgroup, al-
though it was possible that the dipole moment of its
trifluoromethyl group could potentially substitute for
the headgroup interaction with S1P1. We therefore ex-
amined the contributions of the “headgroup” interac-
tions by computational modeling of S1P -SEW2871Figure 4. S1P1 Internalization and Recycling Back to Plasma Mem-
brane
HEK293 cells that were stably transfected with GFP-tagged S1P1
were serum starved, pretreated with cycloheximide (15 g/ml) for
30 min, and stimulated with 100 nM S1P, FTY720-phosphate, 500
nM SEW2871, or SEW2898 for 30 min. Cells were washed and incu-
bated for indicated time points. The fluorescence of the recycled
receptor at each time point was quantified and expressed as per-
cent control. Data represent mean ± SD of fluorescence intensities
of ten randomly selected fields.1complex as well as the receptor interaction with SEW2871
analogs without the trifluoromethyl group. SEW2905 is
the methyl replacement of the trifluoromethyl on the
phenyl ring of SEW2871 (D ring in Figure 1C), whereas
SEW2898 has no substituent on the D ring of SEW2871
(Figure 1C).
The optimal position of SEW2871 in the S1P1 recep-
tor places the D ring trifluoromethyl group in close
proximity to R3.28 (120), E3.29 (121), and R7.34 (292)
(Figure 5A). The electronegative fluorine atoms favor-
ably interact with the cationic R3.28 and R7.34 resi-
dues, whereas the less electronegative carbon of the
trifluoromethyl group interacts with the anionic E3.29
residue. Multiple hydrophobic residues form close con-
tacts with the aromatic rings of SEW2871, including
phenylalanine residues from TM3 (125), TM5 (273), and
TM7 (296) as well as a tryptophan residue from TM5
(269). SEW2905 adopts a similar position (Figure 5B),
although the interactions with R3.28, E3.29, and R7.34
are not as favorable. SEW2898 (Figure 5C) is displaced
toward the extracellular loops relative to the positions
of the other two ligand positions in S1P1. On the other
hand, AFD(R), an S1P analog containing a phosphate
group and an ammonium moiety (Figure 1D), showed a
favorable headgroup interaction with S1P1, as pre-
dicted (Figure 5D).
The optimal location of SEW2871 in the S1P2 recep-
tor model is very poor, with docked energies approxi-
mately 10 kcal/mol less favorable than the S1P1 com-
plexes. No interactions are observed with the polar
residues R3.28 (108), E3.29 (109), or K7.34 (269) (data
not shown). Interactions with aromatic residues in TM3
(125), TM6 (246, 250), and TM7 (273) are also not as
favorable as in S1P1. The poor interactions in the S1P2
receptor can be partially attributed to replacement of
arginine with lysine at position 7.34. An arginine residue
at position 7.34 (292) is unique to S1P1, with lysine oc-
curring in the S1P2 (269) and S1P3 (279) receptors, and
uncharged residues occurring in the S1P4 (G288) and
S1P5 (Q288) receptors.
We then measured the contributions of the head-
group interactions by both mutational analysis and the
testing of structural analogs of SEW2871 in order to con-
firm our computational models. We examined down-
stream kinase activities upon stimulation of site-directed
mutant receptors that define the S1P headgroup in-
teractions to see if the mutant receptors show abol-
ished or significantly diminished S1P responses ob-
served in both wild-type and control mutant receptors.
CHO cells were transiently transfected with four site-
directed mutant receptors, R3.28A, E3.29A, R7.34A, and
N101(2.60)K. The N2.60K mutant was included as a
positive control because N2.60 is located just outside
the ligand binding pocket. This N2.60K mutant receptor
was shown to behave similarly to the wild-type receptor
by radioligand binding, 35S-GTPγS binding, and recep-
tor-internalization assays [31].
CHO cells transfected with the wild-type receptor or
the control N2.60(101)K mutant responded to S1P stim-
ulation, resulting in phosphorylation of ERK2 and Akt
(Figure 6A). However, the ion-pairing defective mutants,
R3.28(120)A, E3.29(121)A, and R7.34(292)A, showed
decreased phosphorylation of ERK1/2 and Akt com-
pared to the wild-type or N2.60K, suggesting that im-
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708Figure 5. Computational Models of the Ligand Binding Pocket Illustrating Ligand-Receptor Interactions
Top panels show a receptor backbone with ribbon shaded from red at the amino terminal end to blue at the carboxy terminal end with select
receptor residues shown as stick models and ligands shown as ball-and-stick models. Bottom panels show a closer view of ligand binding
pocket with ligands shown as ball-and-stick models and select receptor residues shown as stick models. Top panels are shown from a
common perspective to emphasize similarities and differences in ligand position in the different complexes. The bottom panels also share a
common perspective that differs from the top in order to better show the ligand binding pocket. (A) S1P1-SEW2871 complex. (B) S1P1-
SEW2905 complex. (C) S1P1-SEW2898 complex. (D) S1P1-AFD(R) complex.paired ion-pairing interaction between S1P1 and S1P f
tcauses defective downstream kinase activities (Figure
6A). AFD(R)-induced kinase activity was also depen- N
Sdent on these ion-pairing residues but to a lesser extent
(Figure 6E). Interestingly, these ion-pairing defective c
tmutants also showed less phosphorylation of ERK1/2
and Akt than the wild-type receptor upon stimulation m
dwith SEW2871 (Figure 6B), despite its different molecu-
lar structure, supporting the computational model (Fig- t
hure 5A). This suggests that SEW2871 binds to the same
ligand binding pocket of S1P1 as S1P, and the same c
Aamino acid residues that participate in S1P headgroup
interaction are engaged in the formation of S1P1- R
SEW2871 complex.
To assess whether the dipole interactions could con- D
tribute to the potency of SEW2871 on the S1P1 receptor
signal generation, we tested the effect of SEW2871 S
Aanalogs without the trifluoromethyl group on down-
stream kinase activities as well as GTPγ35S assay. W
tSEW2905 and SEW2898 (Figure 1C) had comparable
EC50 values obtained by GTPγ35S assay of 107 ± 45 nMor SEW2905 and 25 ± 23 nM for SEW2898 (compared
o 14 ± 8 nM for SEW2871). The wild-type and control
2.60K mutant receptors responded to SEW2905 and
EW2898 stimulation (Figures 6C and 6D), with signifi-
ant phosphorylation of ERK2 and Akt. This suggests
hat SEW2898 contains the minimum structural require-
ent for S1P1 agonism. These analogs, however, showed
ifferent interactions with mutant receptors, compared
o SEW2871. SEW2905 and SEW2898 require some
eadgroup binding elements in order to recruit signifi-
ant kinase responses, specifically showing diminished
kt and ERK2 responses in the E3.29(121)A and
7.34(292)A mutants but not the R3.28(120)A mutant.
iscussion
1P1-Selective Agonist SEW2871 Activates ERK,
kt, and Rac Pathways
e have recently reported that agonism of S1P1 recep-
or is sufficient to control lymphocyte recirculation,
using S1P1-selective agonist SEW2871 [24]. Studying
S1P1-Selective Agonist Signaling Pathways
709Figure 6. Polar Interaction between S1P1 Receptor and Its Ligands Shown by Site-Directed Mutagenesis of the Ligand Binding Pocket
CHO cells were transfected with R3.28A, E3.29A, R7.34A, and N2.60K S1P1. Cells were serum starved and stimulated with S1P 50 nM (A),
SEW2871 500 nM (B), SEW2905 500 nM (C), SEW2898 500 nM (D), or AFD(R) 50 nM (E). Control cells treated with the vehicle (DMSO or
methanol) showed only the minimal levels of pERK1/2 and pAkt (data not shown). Western blot analyses of phospho-ERK1/2, total ERK1/2,
phospho-Akt, and total Akt levels are shown as representative autoradiograms of three independent experiments. The band intensities of
phosphoproteins were integrated, normalized against total ERK or Akt, and expressed as percentage of the phosphorylation upon agonist
stimulation of wild-type receptor (shown as 100%).
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othetic S1P1 receptor ligands is important in under-
standing which potential signals may be responsible for a
2discrete physiological and pharmacological effects of
such ligands. Using the natural ligand S1P and the s
atetraaromatic S1P1-selective agonist, SEW2871, we
have shown that both ligands activate ERK, Akt, and S
mRac pathways in model cell lines transfected with a sin-
gle subtype (S1P1) of S1P receptors. Modeling and mu- d
itagenesis studies showed that SEW2871 shares signifi-
cant overlap in receptor interactions with S1P, although d
itheir molecular structures are different from each other.
Therefore, this study provides the first evidence that o
tthe structurally unrelated synthetic ligand can bind and
activate S1P1 through interaction similar to the natural S
aligand S1P.
a
6Structure-Activity Relationships of S1P1 Agonists
cStudied by Computational Modeling and Kinase
aActivation Downstream to S1P1
eA computational model of the S1P1 receptor has been
breported that predicts critical salt-bridge interactions of
R3.28, E3.29, and R7.34 with S1P [31]. Subsequent ex-
Samination of site-directed mutants of these residues by
Sradioligand binding, ligand-induced [35S]GTPγS bind-
ring, and receptor internalization assays confirmed the
wrequirement of these residues for specific ligand re-
ecognition [31]. Docking of SEW2871 into the computa-
htional models of S1P1 and S1P2 revealed significant in-
steractions with S1P1 that overlap those of S1P, with
wregard to the volume and length of the hydrophobic in-
fteractions. It also suggests potential ion-dipole interac-
mtions between SEW2871 and the R3.28, R7.34, and
HE3.29 residues that support salt-bridge interactions
pwith the aminophosphate headgroups of S1P (Figure
o5A). In contrast, SEW2871 complex formation with S1P2
Owas not supported (data not shown). One contributor
tto the selectivity difference is position 7.34, at which
narginine appears only in the S1P1 receptor.
dData derived from analysis of these S1P1 receptor
pmutants showed that mutation of any of these three
cresidues (R3.28, E3.29, or R7.34) significantly dimin-
pished the phosphorylation of both Akt and ERK2 by
[both S1P and SEW2871 (Figure 6A and 6B, respec-
otively), providing formal evidence for an interaction be-
qtween SEW2871 and the headgroup-coordinating resi-
tdues, despite the chemical inability of SEW2871 to
aform salt-bridges with the receptor.
tWe further explored the headgroup interactions by
fstudying the activation of kinases by analogs of
[SEW2871 that diminished the molecule’s capability for
smaking ion-dipole interactions by using the wild-type
sand the R3.28A, E3.29A, and R7.34A mutant receptors.
tThe data confirmed the orientation of SEW2871 within
the receptor and were consistent with amino-carboxyl-
ate analogs of SEW2871 [50]. Specifically, substitution H
tof the electron-rich −CF3 group with electron-poor
−CH3 (SEW2905; EC50, 107 ± 45 nM in GTPγS binding) S
i(Figures 1C and 6C) resulted in kinase activation that
no longer depended upon R3.28 because of the dis- d
Grupted ion-dipole interaction but was still abolished by
R7.34A as well as by the E3.29A mutation. b
nRemoval of the substituent from the D phenyl ringSEW2898) (Figure 1C) resulted in a compound that is
ne bond length shorter than SEW2871 or SEW2905
nd that retained the similar potency for S1P1 (EC50,
5 ± 23 nM in GTPγS binding). SEW2898 also showed
omewhat limited headgroup dependency, resulting in
similar pattern of kinase activation to SEW2905.
EW2905 and SEW2898 may therefore define the aro-
atic-hydrophobic binding pocket within S1P1 that
oes not depend upon R3.28 residue for the headgroup
nteraction and, thus, may serve as a useful probe to
efine the role of that residue in lymphopenia induction
n future studies. In addition, the ion-dipole interaction
f SEW2871 does not seem to be necessary for its po-
ency in GTP binding and kinase activation because
EW2905 and SEW2898 without dipole moment were
lso potent agonists for S1P1. The R3.28A mutant was
ctivatable by SEW2905 and SEW2898 (Figures 6C and
D), excluding the possibility that these mutations may
ause a global disruption that makes the receptor un-
ctivatable. In addition, proper folding and cell-surface
xpression of all the mutant receptors were confirmed
y immunofluorescence of Flag tags [31].
1P1 Receptor Internalization and Recycling
1P receptor agonists induced lymphopenia in vivo
apidly, inhibiting entry of bulk lymphocytes into lymph
ithin an hour of ligand infusion, and continuous pres-
nce of agonist was required for maintenance of in-
ibition [24]. Therefore, ERK and Akt phosphorylation
eems to be one of the early downstream effector path-
ays, and their temporary phosphorylation may be suf-
icient to activate further downstream effectors that are
ore directly involved in maintaining lymphopenia.
owever, it has been recently suggested that lympho-
enia arises because of internalization and inactivation
f S1P1 upon FTY720-phosphate stimulation [25, 30].
ur data revealed that SEW2871 recapitulates the ac-
ion of S1P in that both ligands induced receptor inter-
alization and recycling (Figure 4). Both ligands were
ocumented to induce a transient lymphopenia that
ersists only in the presence of ligand [24], and in the
ase of S1P, it requires less than 2-fold elevation in
lasma S1P concentrations to induce lymphopenia
17]. On the other hand, FTY720-phosphate induced
nly internalization but not recycling. This raised a
uestion whether FTY720-phosphate induces func-
ional antagonism [30]. However, FTY720-phosphate
nd its analog AFD(R) induce alterations of lymphocyte
rafficking at very low doses (ED50, 0.01 mg/kg) with
ree ligand concentrations in the low picomolar range
15]. Therefore, the lymphopenia induction with the
ubstoichiometric receptor activation is most likely re-
ult from agonist effects but is unlikely to be func-
ional antagonism.
eadgroup and Hydrophobic Interactions Contribute
o the Potency of S1P1 Agonists
EW2871 has been shown to be a full agonist of S1P1,
nducing activation of Gi/o to 100% of the response in-
uced by the native agonist S1P, as measured by
TPγS binding [24]. However, its potency in receptor
inding and downstream recruitment of the kinase sig-
aling is significantly lower than the charged head-
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711group-containing ligands S1P or AFD(R). Kinase phos-
phorylation induced by AFD(R) (Figures 2A–2C and
Table 1) had an EC50 approximately 3- to 10-fold less
than that induced by S1P and may reflect the impor-
tance of the aromatic substituent within its acyl chain
(Figure 1D). SEW2871 was measurably less potent at
both G protein binding and kinase activation than
AFD(R) and S1P (Table 1). SEW2871 was also less po-
tent at Rac activation (Figure 3B). Therefore, the unique
structure of SEW2871 provides this agonist with S1P1-
selectivity but with lower potency. This difference in po-
tency in kinase activation is maintained in in vivo activ-
ity for the immunosuppression caused by lymphocyte
sequestration.
At least three mechanisms may contribute to differ-
ences in potency of agonism downstream of S1P1.
These include different receptor conformations upon
ligand binding, different rates of receptor activa-
tion/inactivation, and effects through transactivation of
other signaling pathways. The enhanced potency of
AFD(R) for G protein and kinase activation compared
to S1P suggests that the aromatic component of the
AFD tail (Figure 1D) may contribute to its higher po-
tency. In this case, headgroup interactions are equiva-
lent, and differences may reflect changes in receptor
conformation [51] or rate of fractional occupancy.
The relatively low potency of SEW2871 on kinase ac-
tivation may result from hydrophobic-aromatic interac-
tions without headgroup salt-bridge interactions. This
may reflect a slower fractional rate of receptor occu-
pancy with ligands requiring complex hydrophobic-aro-
matic interactions. Conjugated aromatic systems like
those present in the SEW2871 are not very flexible
when compared to S1P or AFD(R). This lack of flexibility
might influence the rate at which the ligands can ac-
cess the buried binding pocket. A potentially slower on
rate would not be as evident in GTPγS binding, an equi-
librium measurement, but would be more apparent in
kinetic interactions such as kinase activation or calcium
flux.
An alternate explanation for the different potency of
kinase recruitment may also reflect different degrees of
pathway transactivation [42, 43]. GPCR-mediated acti-
vation of ERK/MAPK could occur through a number of
pathways. It could take place either in a tyrosine ki-
nase-independent pathway or in a tyrosine kinase-
dependent pathway, which needs receptor tyrosine ki-
nase transactivation [52]. In addition, GPCRs coupled
to G protein can stimulate MAPK through phosphoino-
sitide 3-kinase γ (PI3Kγ) in a Gβγ-dependent manner
[53]. The relative importance of these multiple signaling
tracks depends on cell type and receptor type [52] and
possibly on agonist type. The presence of these multi-
ple tracks for ERK signaling may also contribute to the
differential potency of hydrophobic-aromatic S1P1 ago-
nist inducing kinase activation.
Different ligands thus interact differently with S1P1
and induce signals with different potencies both in this
model system, as well as in lymphocyte trafficking
studies in blood, thymus [15], and lymph node in vivo
[24]. The model system underestimates the potential
complexities in vivo by not taking into account G pro-
tein promiscuity and tissue-dependent regulation of
GPCRs by adaptors and by GTPases. Well-definedchemical probes of protein function will further the un-
derstanding of the molecular mechanisms underlying
the different potencies of S1P receptor activation in
both model systems and primary cells and tissues.
These studies over time will shed light on mechanisms
by which S1P receptors couple to multiple downstream
effector functions and differentially regulate multiple
physiological events. They will also provide a funda-
mental basis that could exploit these molecular sys-
tems on therapies for immune and cardiovascular dis-
eases as well as cancer.
Significance
It is possible to define off-the-shelf compounds from
high-throughput screening that replicate complex hy-
drophobic and headgroup interactions of natural li-
gands, activate multiple transduction pathways distal
to their cognate receptor, provide structure-activity
relationship, and allow chemical proof-of-concept
in vivo. Specifically, the compound we identified was
not only functionally S1P-like but also receptor sub-
type selective and did not require chemical optimiza-
tion. In this study, we show that S1P1-selective syn-
thetic agonist SEW2871 activates G protein, ERK, Akt,
and Rac pathways as well as S1P1 internalization and
recycling, recapitulating the action of the natural li-
gand S1P. Molecular modeling and receptor mutagen-
esis revealed that in addition to its proposed hy-
drophobic interactions with the receptor, SEW2871
requires the presence of polar receptor residues that
support salt-bridge interactions with the S1P head-
group. Comparison of the natural ligand for S1P1,
S1P, with the synthetic agonists, SEW2871 and its an-
alogs, illustrates significant contributions of head-
group interactions into the signal generation down-
stream of Gi/o protein activation. These findings are
of both fundamental and therapeutic importance.
Sphingosine 1-phosphate (S1P) is a pleiotropic lyso-
phospholipid that affects cell growth, cardiovascular
function, and immune cell trafficking. Although we
have begun to clarify mechanisms governing egress
of lymphocytes from lymph nodes to lymph, the criti-
cal details of mechanism on the cellular level need
to be resolved [24, 54]. Our data raise fundamental
mechanistic questions of how ligands, such as S1P,
AFD(R), and SEW2871, induce lymphopenia possibly
through kinase and Rac activation. Our findings on
SEW2871 and S1P agonism with receptor recycling
suggest that functional antagonism may not be es-
sential for induction of rapidly reversible lymphope-
nia. SEW2871 and its analogs shed light on properties
of S1P1 agonists necessary for the induction and
maintenance of immunosuppression. Understanding
the basis of S1P1 receptor regulation of immune-cell
trafficking will help developing selective immunother-
apeutic treatment needed for autoimmune diseases
and transplantation rejection.
Experimental Procedures
S1P Receptor Agonists
Sphingosine 1-phosphate (S1P) was purchased from BioMol (Plym-
outh Meeting, PA). SEW2871 (5-[4-phenyl-5-trifluoromethyl-thio
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712phen-2-yl]-3-[3-trifluoromethyl-phenyl]-1,2,4-oxadiazole), SEW2905 R
[(3-[4-methylphenyl]-5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-1,2,
4-oxadiazole), and SEW2898 (3-phenyl-5-[4-phenyl-5-(trifluoro- t
tmethyl)-2-thienyl]-1,2,4-oxadiazole) were purchased from Maybridge
(Tintagel, Cornwall, UK). AFD(R), phosphate ester of 2-amino-4- b
7(4-heptyloxyphenyl)-2-methyl butanol, was a kind gift of Novartis
Pharma (Basel, Switzerland, Volker Brinkmann). f
b
o
Cell Culture and Transfection
Chinese hamster ovary (CHO) cells stably expressing human S1P R
receptors, S1P1-CHO and S1P3-CHO cells, were kindly provided C
by Danilo Guerini (Novartis Pharma). They were maintained in 5
RPMI1640 (Life Technologies, Gibco) containing 10% fetal bovine c
serum, 0.5 mg/ml G418, 50 g/ml gentamycin, 100 units/ml penicil- A
lin, 100 g/ml streptomycin, and 10 mM HEPES. For the site-di- (
rected mutant-receptor study, CHO cells in a 6-well plate were 1
transfected with 1 g of plasmid DNA (pcDNA3 containing R3.28A, t
E3.29A, R7.34A, or N2.60K S1P1 receptor construct as described (
[31]), 6 l PLUS reagent, and 4 l LipofectAMINE reagent (Life f
Technologies, Gibco). After 4 hr, the transfection medium was re- a
placed with fresh medium. After 18 hr of growth, the transfected m
cells were serum starved for 6 hr and stimulated for 5 min with b
S1P, AFD(R), SEW2871, SEW2905, or SEW2898 diluted to various R
concentrations. Cells were lysed as follows for Western blotting. m
Transfection efficiency was measured in the cells on cover slips
from a duplicate plate. The cells were fixed for 10 min with 4% Rparaformaldehyde in PBS, and excess paraformaldehyde was
Hquenched with 50 mM NH4Cl in PBS. Cells were then permeabilized wfor 30 min with 0.1% Triton X-100 in PBS and incubated for 30 min
fin blocking buffer (PBS, 0.1% Triton X-100, 5% BSA, 5% normal
goat serum). Cells were subsequently incubated for 1 hr with anti-
uFlag antibody in PBS/0.1% Triton X-100/5% BSA/5% normal goat
Sserum, rinsed in PBS/0.1% Triton X-100 three times, and incubated
Dfor 30 min in the dark with Alexa Fluor 488-conjugated goat anti-
Tmouse IgG and Alexa Fluor 633-conjugated ToPro3 (Molecular
qProbes). Cells were rinsed three times, mounted, and viewed with
an Olympus BX61 scanning confocal fluorescence microscope. All
Cthe mutant receptors were equivalently cell-surface expressed
Rwhen examined for immunofluorescence of Flag tags as de-
Ascribed [31].
S
t
sWestern Blotting
tControl CHO cells and the CHO cells stably transfected with human
tS1P1 or S1P3 were cultured to 50% confluence on a 6-well plate in
tcomplete RPMI1640 supplemented with 10% FBS. Cells were se-
Trum starved for 16 hr and stimulated with S1P, AFD(R), or SEW2871
idiluted to various concentrations in the serum-free medium with
h0.1% fatty-acid-free BSA. At 5 min, 1 hr, or 4.5 hr, cells were lysed
Rin 50 mM Tris (pH 8.0), 125 mM NaCl, 20 mM CHAPS, 2 mM di-
Athiothreitol, 1 mM EDTA, 2 mM Na3VO4, 10 mM NaF, 1 mM PMSF,
wand protease inhibitor cocktail (Roche, Germany). For the study of
Bpertussis toxin (PTx) inhibition, cells were incubated with PTx at
[the final concentration of 100 ng/ml for 3 hr, prior to agonist stimu-
Tlation. Cell lysates were analyzed by Western blotting after sep-
oaration on 10% SDS-PAGE with mouse monoclonal anti-phos-
wpho-ERK1/2 antibody (sc-7383; Santa Cruz Biotechnology) and
crabbit polyclonal anti-phospho-Akt antibody (BD Biosciences). To-
stal ERK1 and ERK2 were detected with a rabbit-affinity-purified
Apolyclonal anti-ERK antibody (sc-94; Santa Cruz Biotechnology),
0and total Akt was detected with a rabbit-affinity-purified polyclonal
Ranti-Akt1 antibody (BD Biosciences). Band intensities correspond-
Aing to pERK1, pERK2, and pAkt were quantitated by image analysis
w(Kodak 1D Scientific Imaging Systems). Amounts of pERK1/2 and
tpAkt were normalized for the total amounts of ERK1/2 and Akt.
s
a
TMembrane Preparation and Receptor Activation Assay
Membranes were prepared from CHO cells expressing human S1P1 w
mfor use in ligand and 35S-GTPγS binding studies as described [17].
For 35S-GTPγS binding assay, serial dilutions of S1P, AFD(R), t
uSEW2871, SEW2905, or SEW2898 were added to membranes (1 to
10 g protein/well) and assayed as described [17]. seceptor Binding Assay
33P]-S1P (final concentration of 83 pM) was added to serial dilu-
ions of S1P or AFD(R) in a 96-well plate. Assays were initiated with
he addition of 25 g membrane protein of S1P1-CHO cell mem-
ranes in a final volume of 200 l assay buffer (50 mM HEPES [pH
.5], 5 mM MgCl2, 1 mM CaCl2, 15 mM sodium fluoride, and 1%
atty-acid-free bovine serum albumin). Binding mixtures were incu-
ated for 60 min at room temperature and terminated by filtration
ver Packard GF/B filter plates as described [54, 55].
ac-Activation Assay
ells were serum starved for 16 hr and stimulated with S1P (50 nM,
00 nM, or vehicle control) or SEW2871 (500 nM, 5 M, or vehicle
ontrol) in the serum-free medium with 0.1% fatty-acid-free BSA.
t 2 min and 5 min, cells were lysed in 500 l ice-cold lysis buffer
50 mM Tris [pH 8.0], 500 mM NaCl, 0.5% NP-40, 1 mM EDTA,
mM MgCl2, and protease inhibitor cocktail) containing 20 g GST-
agged p21 binding domain of p21-activated protein kinase 1
PAK1) [47]. The cell lysates were centrifuged at 16,000 × g at 4°C
or 3 min, and 40 l prewashed 50% GSH-Sepharose beads were
dded to the supernatant. The mixture was incubated at 4°C for 30
in, and the beads were washed twice in lysis buffer. The proteins
ound to the beads were eluted with SDS sample buffer. Activated
ac GTPases were detected by Western blotting with a mouse
onoclonal anti-Rac antibody (Upstate Biotech, Lake Placid, NY).
eceptor Internalization and Recycling
EK293 cells that were stably transfected with GFP-tagged S1P1
ere grown in DMEM medium with 2% charcoal-stripped serum
or 2 days [28]. Cells were pretreated with cycloheximide (15
g/ml) for 30 min to block the synthesis of new S1P1 and stim-
lated with 100 nM S1P, FTY720-phosphate, 500 nM SEW2871, or
EW2898 for 30 min. Cells were washed and replenished with plain
MEM and cycloheximide and incubated for indicated time points.
he fluorescence of the recycled receptor at each time point was
uantified and expressed as percent control.
omputational Homology Modeling
esidue Nomenclature
mino acids within the transmembrane (TM) domains of S1P1 and
1P2 can be assigned index positions to facilitate comparison be-
ween receptors with different numbers of amino acids, as de-
cribed by Weinstein and coworkers [56]. An index position is in
he format x.xx. The first number denotes the TM domain in which
he residue appears. The second number indicates the position of
hat residue relative to the most highly conserved residue in that
M domain, which is arbitrarily assigned position 50. E3.29, then,
ndicates the relative position of this arginine in TM 3 relative to the
ighly conserved arginine 3.50 in the E(D)RY motif [56].
eceptor-Model Development: S1P1
model of human S1P1 (GenBank accession number AFP23365)
as developed by homology to a model of rhodopsin (Protein Data
ank entry 1boj) in a manner described by Parrill and coworkers
31, 57]. Briefly, the rhodopsin model was used to generate TM1–
M6, whereas the structure for the seventh TM was based on TM7
f the dopamine D2 receptor model [58]. The preliminary model
as further refined by converting all cis amide bonds to the trans
onfiguration and by manually rotating side chains at polarity-con-
erved positions to optimize hydrogen bonding between TM. The
MBER94 force field [59] was utilized to optimize the receptor to a
.1 kcal/mol · Å root mean square gradient.
eceptor-Model Development: S1P2
model of human S1P2 (GenBank accession number AFP23365)
as developed by homology to S1P1. Alignment of the S1P recep-
or sequences was performed with the MOE software package (ver-
ion 2003.01, Chemical Computing Group, Montreal, Canada). The
lignment was optimized by the manual removal of gaps within the
M. A preliminary model was generated by homology modeling
ith default parameters and subsequently manually refined to opti-
ize interhelical hydrogen bonding. Cis-amide bonds present in
he loop regions were converted to the trans conformation by man-
al rotation followed by the minimization of two residues on either
ide of the amide bond to a root mean square (RMS) gradient of
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7130.1 kcal/mol · Å with the MMFF94 forcefield [60]. After these manual
refinements, the entire receptor model was optimized with the
MMFF94 forcefield to an RMS gradient of 0.1 kcal/mol · Å.
Ligand-Model Development
Computational models of SEW2871, SEW2905, and SEW2898 (Fig-
ure 1C) were built with the MOE software package. In order to
maintain the delocalized pi stabilization of the ligand, rings B, C,
and D remained coplanar throughout the docking calculation. The
steric bulk associated with the thiophene CF3 substituent prevents
ring A from adopting a conformation that is coplanar with ring B;
hence, there was free rotation of the bond between rings A and B.
The MMFF94 force field was invoked for the subsequent geome-
try optimizations.
Docking
Using the AUTODOCK 3.0 software package [61], we docked the
SEW2871 analogs into the S1P1 and S1P2 receptor models, and
these complexes were evaluated based on electrostatic and other
nonbonded interactions between the ligand and receptor. The
complexes exhibiting the best interactions were geometry opti-
mized with the MMFF94 force field [60], and the lowest energy
complex after minimization was subjected to molecular dynamics
simulations. Default docking parameters were used with the follow-
ing exceptions: 3000 iterations were used in the local search phase,
each of the 20 docking runs continued for 20,000 generations with
a maximum of 1 × 109 energy evaluations.
Molecular Dynamics
An electrostatic potential for SEW2871 was derived from a
quantum mechanical calculation at the HF/6-31G* level of theory.
ANTECHAMBER used this restricted electrostatic potential to de-
rive partial atomic charges compatible with the AMBER94 force
field. A 500 ps molecular dynamics simulation was computed with
the MOE software (NVT ensemble, 1 fs timesteps, 60 ps equilibra-
tion phase, 300 K), and the lowest energy complex was minimized
with the AMBER94 force field. The optimized snapshot from the
MD simulation is presented as the final model of the S1P1 complex
with SEW2871.
Supplemental Data
Supplemental Data include two figures and can be found with this
article online at http://www.chembiol.com/cgi/content/full/12/6/
703/DC1/.
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